The startup develops a proprietary platform for the intracellular delivery of bioactive molecules, utilizing advanced transduction methods to introduce proteins, peptides, nanobodies, and small oligonucleotides into patient cells. This technology enables the research community to create targeted therapies for genetic diseases and cancer by facilitating precise molecular interventions within cells.
Funding
$2.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current methods of delivering gene-editing complexes into cells often suffer from limitations in efficiency and safety, hindering the development of effective cell and gene therapies for diseases like cancer and genetic disorders. Traditional viral delivery methods can trigger unwanted immune responses and have limited cargo capacity, while non-viral methods often lack the necessary efficiency for therapeutic applications.
Solution
NTrans Technologies has developed a GMP-ready, non-viral delivery platform that leverages macropinocytosis, a natural cellular uptake process, to deliver gene-editing technologies with precision and security. This modular platform is designed for easy integration with therapeutic development processes, setting a new standard in cell and gene therapy. The technology facilitates the delivery of CRISPR/Cas9, base editors, and prime editors into cells, paving the way for precise genome editing without causing double-strand breaks, enhancing the safety and reliability of gene editing. By improving the delivery of gene-editing complexes, NTrans aims to make genetic treatments safer, more effective, and more accessible.
Target Audience
NTrans Technologies primarily serves strategic partners involved in therapeutic development, particularly those focused on cell and gene therapies for immuno-oncology (CAR-T and TCR therapies) and hematology.
Features
- Non-viral delivery system utilizing a natural cellular uptake mechanism (macropinocytosis)
- High gene editing efficiency and cell viability
- Excellent intrinsic safety profile
- Simple and scalable implementation
- GMP-ready platform suitable for clinical applications
- Modular design for easy integration with existing therapeutic workflows
- Facilitates delivery of CRISPR/Cas9, base editors, and prime editors
- Targeted delivery enhances the accuracy of cancer-targeting immune responses in CAR-T cell therapy